Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pulmonx (LUNG) Revenue (2019 - 2025)

Pulmonx (LUNG) has disclosed Revenue for 7 consecutive years, with $21.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Revenue rose 5.47% to $21.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $91.7 million, a 15.59% increase, with the full-year FY2024 number at $83.8 million, up 22.01% from a year prior.
  • Revenue was $21.5 million for Q3 2025 at Pulmonx, down from $23.9 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $23.9 million in Q2 2025 to a low of $9.2 million in Q1 2021.
  • A 5-year average of $17.0 million and a median of $17.2 million in 2023 define the central range for Revenue.
  • Peak YoY movement for Revenue: skyrocketed 232.24% in 2021, then increased 1.82% in 2022.
  • Pulmonx's Revenue stood at $13.7 million in 2021, then increased by 12.53% to $15.4 million in 2022, then rose by 24.98% to $19.3 million in 2023, then increased by 23.28% to $23.8 million in 2024, then dropped by 9.52% to $21.5 million in 2025.
  • Per Business Quant, the three most recent readings for LUNG's Revenue are $21.5 million (Q3 2025), $23.9 million (Q2 2025), and $22.5 million (Q1 2025).